Take part in research

Share

Aa-+

Clinical studies

BRAIN-AF

The BRAIN-AF clinical study is conducted by a team of specialists and researchers from the Montreal Heart Institute (MHI) in collaboration with the Canadiean Stroke Prevention Intervention Network, the phamaceutical company Bayer, the Montreal Health Innovations Coordinating Center (MHICC) and the MHI Foundation.

The study, which is a world first, aims to demonstrate that taking low dose of rivaroxaban, an anticoagulant, could decrease the risk of developing cognitive impairment, transient ischemic attack or stroke in patients with atrial fibrillation. This clinical study was announced on november 19th 2015.

You whish to learn more about this study? View our French Virtual Conference. HERE

Participate in this clinical study:

The MHI BRAIN-AF team is currently seeking participants for this study. Patients under 60 years of age with atrial fibrillation are potentially admissible for this clinical study. If you would like to get further information or if you are interested in participating in this study, please contact:

Research coordinator :  Diane David
Telephone :    514-376-3330 poste 2884
E-mail: diane.david@icm-mhi.org

What does BRAIN-AF stand for?

BRAIN-AF is the acronym for Blended Randomized trial of Anticoagulation to prevent Ischemic stroke and Neurocognitive impairment in Atrial Fibrillation.

BRAIN-AF

The BRAIN-AF clinical study is conducted by a team of specialists and researchers from the Montreal Heart Institute (MHI) in collaboration with the Canadiean Stroke Prevention Intervention Network, the phamaceutical company Bayer, the Montreal Health Innovations Coordinating Center (MHICC) and the MHI Foundation.

The study, which is a world first, aims to demonstrate that taking low dose of rivaroxaban, an anticoagulant, could decrease the risk of developing cognitive impairment, transient ischemic attack or stroke in patients with atrial fibrillation. This clinical study was announced on november 19th 2015.

You whish to learn more about this study? View our French Virtual Conference. HERE

Participate in this clinical study:

The MHI BRAIN-AF team is currently seeking participants for this study. Patients under 60 years of age with atrial fibrillation are potentially admissible for this clinical study. If you would like to get further information or if you are interested in participating in this study, please contact:

Research coordinator :  Diane David
Telephone :    514-376-3330 poste 2884
E-mail: diane.david@icm-mhi.org

What does BRAIN-AF stand for?

BRAIN-AF is the acronym for Blended Randomized trial of Anticoagulation to prevent Ischemic stroke and Neurocognitive impairment in Atrial Fibrillation.